Evidence map›Paper›PMID 32157332›Full record

ArticleDiabetologia2020

Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8

Stephanie J Hanna, Wendy E Powell, Anna E Long, Emma J S Robinson, Joanne Davies, Clare Megson, Alexandra Howell, Taz J Jones, Kristin Ladell, David A Price and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Clinical and experimental treatment of type 1 diabetes.Clinical and experimental immunology · 2022
    Review
  18. Article
  19. Frontiers in endocrinology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stephanie J HannaDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.ORCID 0000-0002-0821-4498
Wendy E PowellDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Anna E LongDiabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
Emma J S RobinsonDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Joanne DaviesDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Clare MegsonDiabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
Alexandra HowellDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Taz J JonesDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Kristin LadellDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Colin M DayanDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
Alistair J K WilliamsDiabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
Kathleen M GillespieDiabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
F Susan WongDivision of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK. wongfs@cardiff.ac.uk.

Funding

Diabetes UK 18/0005778Juvenile Diabetes Research Foundation 3-APF-2018-591-A-NWellcome Trust 100326/Z/12/Z
6 · The paper itself

Abstract

aims/hypothesisThe aim of this study was to characterise islet autoantibody profiles and immune cell phenotypes in slow progressors to type 1 diabetes.

methodsImmunological variables were compared across peripheral blood samples obtained from slow progressors to type 1 diabetes, individuals with newly diagnosed or long-standing type 1 diabetes, and healthy individuals. Polychromatic flow cytometry was used to characterise the phenotypic attributes of B and T cells. Islet autoantigen-specific B cells were quantified using an enzyme-linked immunospot (ELISpot) assay and islet autoantigen-specific CD8

resultsIslet autoantibodies were lost over time in slow progressors. Various B cell subsets expressed higher levels of CD95 in slow progressors, especially after polyclonal stimulation, compared with the corresponding B cell subsets in healthy donors (p < 0.05). The phenotypic characteristics of CD4 CONCLUSIONS/

interpretationIn this study, we found that slow progression to type 1 diabetes was associated with a loss of islet autoantibodies and a distinct B cell phenotype, consistent with enhanced apoptotic regulation of peripheral autoreactivity via CD95. These phenotypic changes warrant further studies in larger cohorts to determine their functional implications.

Indexed as

AutoantibodiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1fas ReceptorFlow CytometryHumansProinsulinAutoantibodiesfas ReceptorProinsulinAutoantibodiesB cellsCD95DcR3ELISpotPeptide-HLA class I tetramersProinsulinSlow progressors to type 1 diabetesT cells

Identifiers

PMID32157332
PMCPMC7228996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.